These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 8608502)

  • 21. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
    Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen.
    Tsai SC; Kao CH; Wang SJ
    Neoplasma; 1996; 43(1):27-9. PubMed ID: 8843956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
    Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [CYFRA 21-1: a new marker of epidermoid cancer of the bronchi. Comparison with 3 other markers].
    Pujol JL; Grenier J; Ray P; Gautier V; Aouta MD; Michel FB
    Presse Med; 1993 Jun; 22(22):1039-42. PubMed ID: 7692432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum tumor marker CYFRA 21-1 in the diagnostics of squamous cell lung cancer--comparison with CEA.
    Berzinec P; Zuffová H; Letkovicová M; Arpásová M
    Neoplasma; 1996; 43(3):159-61. PubMed ID: 8841502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer.
    Schneider J; Velcovsky HG; Morr H; Katz N; Neu K; Eigenbrodt E
    Anticancer Res; 2000; 20(6D):5053-8. PubMed ID: 11326667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative studies of CAM 123-6 and carcinoembryonic antigen for the serological detection of pulmonary adenocarcinoma.
    Kohno N; Hirasawa Y; Kondo K; Fujioka S; Fujino S; Abe M; Yokoyama A; Hiwada K; Watanabe K; Nishimura J
    Cancer Detect Prev; 1997; 21(2):124-8. PubMed ID: 9101072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer.
    Kainz C; Sliutz G; Mustafa G; Bieglmayr C; Koelbl H; Reinthaller A; Gitsch G
    Gynecol Oncol; 1995 Mar; 56(3):402-5. PubMed ID: 7535720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Role of biological tumor markers CEA, Cyfra-21, NSE, TU M2-PK in diagnosis and treatment of lung cancer].
    Lazarev SM; Massard Zh; Reshetov AV; Nikolaev GV; Volgin GN; Osipov EV; Lomteva EIu; Nokhrin AV; Kakysheva OE
    Vestn Khir Im I I Grek; 2010; 169(1):39-43. PubMed ID: 20387605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Lung cancer].
    Komagata H; Yoneda S
    Gan To Kagaku Ryoho; 2004 Oct; 31(10):1609-13. PubMed ID: 15508459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sputum carcinoembryonic antigen, neuron-specific enolase and cytokeratin fragment 19 levels in lung cancer diagnosis.
    Kalomenidis I; Dimakou K; Kolintza A; Vlami K; Papadakis M; Sotiropoulou C; Orphanidou D; Roussos C; Papiris S
    Respirology; 2004 Mar; 9(1):54-9. PubMed ID: 14982602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients.
    Koga H; Eguchi K; Shinkai T; Tamura T; Ohe Y; Oshita F; Saijo N; Kondo H; Oki K; Okura H
    Jpn J Clin Oncol; 1994 Oct; 24(5):263-8. PubMed ID: 7526016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.
    Molina R; Filella X; Augé JM; Bosch E; Torne A; Pahisa J; Lejarcegui JA; Rovirosa A; Mellado B; Ordi J; Biete A
    Anticancer Res; 2005; 25(3A):1765-71. PubMed ID: 16033097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A fuzzy-classifier using a marker panel for the detection of lung cancers in asbestosis patients.
    Schneider J; Bitterlich N; Kotschy-Lang N; Raab W; Woitowitz HJ
    Anticancer Res; 2007; 27(4A):1869-77. PubMed ID: 17649786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
    Ebert W; Muley T; Drings P
    Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic value of CEA, CYFRA 21-1, NSE and CA 125 assay in serum and pleural effusion of patients with lung cancer.
    Wu GP; Ba J; Zhao YJ; Wang EH
    Acta Cytol; 2007; 51(4):679-80. PubMed ID: 17718156
    [No Abstract]   [Full Text] [Related]  

  • 38. Performance characteristics of an automated assay for the quantitation of CYFRA 21-1 in human serum.
    Patel JL; Erickson JA; Roberts WL; Grenache DG
    Clin Biochem; 2010 Dec; 43(18):1449-52. PubMed ID: 20875814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis.
    Pastor A; Menéndez R; Cremades MJ; Pastor V; Llopis R; Aznar J
    Eur Respir J; 1997 Mar; 10(3):603-9. PubMed ID: 9072992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
    Ma S; Shen L; Qian N; Chen K
    Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.